Ahmed GARDOUH, Alshimaa GAMAL, Shadeed GAD

Formulation and pharmacokinetic evaluation of rifampicin solid lipid nanoparticles

This study aims to optimize RIF loaded solid lipid nanoparticles (RIF-SLNs) to sustain its release andenhance its oral absorption and bioavailability. RIF loaded SLNs were formulated by a modified micro emulsionbased technique using two different lipids (Cetyl palmitate and Glyceryl monostearate) and two different surfactants(Tween®80 and Poloxamer 188). Particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (E.E), drug loading capacity (L.C), in vitro drug release, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM) were determined for RIF loaded SLNs formulae. Pharmacokinetic study was performed on optimized RIF-SLNs, marketed RIF and pure drug suspension in Wistar rats. The particle size, PDI, E.E% and L.C% of optimized formula were recorded as 0.183 µm, 0.420, -34.7 mV, 80.8% and 0.216%, respectively. In vitro release studies suggested that all SLNs formulae possessed a burst release createdfrom the unloaded drug and adsorbed drug molecules at SLNs surface then sustained release due to diffusion of drug from lipid matrix over a period of 120 h. From the release kinetics data, the release rate of RIF from all formulae fitted into Higuchi’s diffusion model. Pharmacokinetic study showed significant enhancement in RIF-SLNs relative bioavailability 5.86 and 2.33 folds in comparison with pure RIF suspension and marketed RIF. RIF loaded SLNs were formulated successfully by a modified micro emulsion-based method. Also, oral drug delivery can be enhanced bySLNs which showed improvement in the oral bioavailability of the drug.

PDF

___

[1] Mulla JAS, Hiremath SP, Sharma NK. Repaglinide Loaded Solid Lipid Nanoparticles: Design and Characterization. RGUHS J Pharm Sci. 2012; 2(4): 41-49.
[2] Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-Loaded Solid Lipid Nanoparticles: Effect of Using Different Surfactants/Stabilizers on Physicochemical Properties of Nanoparticles. DARU J Pharm Sci. 2015; 23(1):46. [CrossRef]
[3] Boonme P, Souto EB, Wuttisantikul N, Jongjit T, Pichayakorn W. Influence of Lipids on the Properties of Solid Lipid Nanoparticles from Microemulsion Technique. Eur J Lipid Sci Technol. 2013; 115(7): 820-824. [CrossRef]
[4] Aboutaleb E, Noori M, Gandomi N, Atyabi F, Fazeli MR, Jamalifar H, Dinarvand R. Improved Antimycobacterial Activity of Rifampin Using Solid Lipid Nanoparticles. Int Nano Lett. 2012; 2(1): 33. [CrossRef]
[5] Chokshi NV, Khatri HN, Patel MM. Formulation, Optimization, and Characterization of Rifampicin-Loaded Solid Lipid Nanoparticles for the Treatment of Tuberculosis. Drug Dev Ind Pharm. 2018; 44(12): 1975-1989. [CrossRef]
[6] Shimomura H, Nogami R, Shigeno A, Shimada S, Aoyama T. Influence of Food on Rifampicin Pharmacokinetics in Rats. Biol Pharm Bull. 2016; 39(1): 49-53. [CrossRef]
[7] Mona MA, Amira MM. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers of Tolnaftate: Design, Optimization and In-Vitro Evaluation. Int J Pharm Pharm Sci. 2016; 8(1): 380-385.
[8] Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of Quality by Design Approach for İntranasal Delivery of Rivastigmine Loaded Solid Lipid Nanoparticles: Effect on Formulation and Characterization Parameters. Eur J Pharm Sci. 2015; 78: 54-66. [CrossRef]
[9] Baek JS, Shin SC, Cho CW. Effect of Lipid on Physicochemical Properties of Solid Lipid Nanoparticle of Paclitaxel. J Pharm Investig. 2012; 42(5): 279-283. [CrossRef]
[10] Golmohammadzadeh S, Mokhtari M, Jaafari MR. Preparation, Characterization and Evaluation of Moisturizing and UV Protecting Effects of Topical Solid Lipid Nanoparticles. Braz J Pharm Sci. 2012; 48(4): 683-690. [CrossRef]
[11] Palie N, Das MK. Preparation and Characterization of Lornoxicam Loaded Solid Lipid Nanoparticles Made from Different Lipids. Int J Pharm Pharm Sci. 2013; 5 Suppl 4: 438-442.
[12] Ding Y. PhD Thesis. Lipid Nanoparticles for Topical Delivery: Solid Lipid Nanoparticles (SLN) & Smartlipids. Department of Pharmaceutics, the Institute of Pharmacy, Freie University, Berlin, Germany, 2018.
[13] Sharma VK. Solid Lipid Nanoparticles System: an Overview. Int J Res Pharm Sci. 2011; 2(3): 450-461.
[14] Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and Evaluation of Nitrendipine Loaded Solid Lipid Nanoparticles: İnfluence of Wax and Glyceride Lipids on Plasma Pharmacokinetics. Int J Pharm. 2007; 335(1-2): 167-175. [CrossRef]
[15] Shenoy VS, Gude RP, Murthy RSR. In Vitro Anticancer Evaluation of 5-Fluorouracil Lipid Nanoparticles Using B16F10 Melanoma Cell Lines. Int Nano Lett. 2013; 3(1): 36. [CrossRef]
[16] Patel M. MSc Thesis. Development, Characterization and Evaluation of Solid Lipid Nanoparticles as a Potential Anticancer Drug Delivery System. College of Pharmacy and Pharmaceutical Science, University of Toledo, Toledo, Ohio, United States, 2012.
[17] Khalil RM, El-Bary AA, Kassem MA, Ghorab MM, Ahmed MB. Solid Lipid Nanoparticles for Topical Delivery of Meloxicam: Development and İn Vitro Characterization. Eur Sci J. 2013; 9 Spec No. 3: 779-798.
[18] Vivek K, Reddy H, Murthy RS. Investigations of the Effect of the Lipid Matrix on Drug Entrapment, İn Vitro Release, and Physical Stability of Olanzapine-Loaded Solid Lipid Nanoparticles. AAPS PharmSciTech. 2007; 8(4): 16-24. [CrossRef]
[19] Abdelbary G, Fahmy RH. Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization. AAPS PharmSciTech. 2009; 10(1): 211-219. [CrossRef]
[20] Müller RH, Mäder K, Gohla S. Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery–a Review of the State of the Art. Eur J Pharm Biopharm. 2000; 50(1): 161-177. [CrossRef]
[21] Mohyeldin SM, Mehanna MM, Elgindy NA. The Relevancy of Controlled Nanocrystallization on Rifampicin Characteristics and Cytotoxicity. Int J Nanomedicine. 2016; 11: 2209-2222. [CrossRef]
[22] Paolicelli P, Cerreto F, Cesa S, Feeney M, Corrente F, Marianecci C, Casadei MA. Influence of the Formulation Components on the Properties of the System SLN-Dextran Hydrogel for the Modified Release of Drugs. J Microencapsul. 2009; 26(4): 355-364. [CrossRef]
[23] Ghaderkhani J, Yousefimashouf R, Arabestani M, Roshanaei G, Asl SS, Abbasalipourkabir R. Improved Antibacterial Function of Rifampicin-Loaded Solid Lipid Nanoparticles on Brucella Abortus. Artif Cells Nanomed Biotechnol. 2019; 47(1): 1181-1193. [CrossRef]
[24] Singh H, Jindal S, Singh M, Sharma G, Kaur IP. Nano-Formulation of Rifampicin with Enhanced Bioavailability: Development, Characterization and İn-Vivo Safety. Int J Pharm. 2015; 485(1-2): 138-151. [CrossRef]
[25] Rahman Z, Zidan AS, Khan MA. Non-Destructive Methods of Characterization of Risperidone Solid Lipid Nanoparticles. Eur J Pharm Biopharm. 2010; 76(1): 127-137. [CrossRef]
[26] Shazly GA, Alshehri S, Ibrahim MA, Tawfeek HM, Razik JA, Hassan YA, Shakeel F. Development of Domperidone Solid Lipid Nanoparticles: İn Vitro and İn Vivo Characterization. AAPS PharmSciTech. 2018; 19(4): 1712-1719. [CrossRef]
[27] Patil H, Feng X, Ye X, Majumdar S, Repka MA. Continuous Production of Fenofibrate Solid Lipid Nanoparticles by Hot-Melt Extrusion Technology: a Systematic Study Based on a Quality by Design Approach. AAPS J. 2015; 17(1):194-205. [CrossRef]
[28] Stets S, Tavares TM, Peralta-Zamora PG, Pessoa CA, Nagata N. Simultaneous Determination of Rifampicin and İsoniazid in Urine and Pharmaceutical Formulations by Multivariate Visible Spectrophotometry. J Braz Chem Soc. 2013; 24(7): 1198-1205.
[29] Aljaeid BM, Hosny KM. Miconazole-Loaded Solid Lipid Nanoparticles: Formulation and Evaluation of a Novel Formula with High Bioavailability and Antifungal Activity. Int J Nanomedicine. 2016; 11: 441-447. [CrossRef]
[30] Shaker S, Gardouh AR, Ghorab MM. Factors Affecting Liposomes Particle Size Prepared by Ethanol İnjection Method. Res Pharm Sci. 2017; 12(5): 346-352.
[31] Triplett MD. PhD Thesis. Enabling Solid Lipid Nanoparticle Drug Delivery Technology by İnvestigating İmprovedProduction Techniques. Ohio State University, Columbus, Ohio, United States, 2004.
[32] Ghorab M, Gardouh A, Gad S. Effect of Viscosity, Surfactant Type and Concentration on Physicochemical Properties of Solid Lipid Nanoparticles. Int J Pharm Pharm Sci. 2015; 7(3): 145-153.
[33] Begum A, Basava R, Rao R. Simultaneous Estimation of Rifampicin and İsoniazid in Combined Dosage Form By a Simple UV Spectrophotometric Method. Pharm Lett. 2013; 5(3): 419-426.
[34] Prasanthi B, Ratna JV, Phani RC. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Rifampicin, İsoniazid and Pyrazinamide in Human Plasma. J Anal Chem. 2015; 70(8): 1015-1022. [CrossRef]
[35] Nasr A, Gardouh A, Ghorab M. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. Pharmaceutics. 2016; 8(3): 20. [CrossRef]
[36] Akhtar N, Talegaonkar S, Khar RK, Jaggi M. Self-Nanoemulsifying Lipid Carrier System for Enhancement of Oral Bioavailability of Etoposide by P-Glycoprotein Modulation: İn Vitro Cell Line and İn Vivo Pharmacokinetic İnvestigation. J Biomed Nanotechnol. 2013; 9(7): 1216-1229. [CrossRef